Maqsood Yaqub
YOU?
Author Swipe
View article: Supplementary Table S2 from [<sup>18</sup>F]FDG and [<sup>18</sup>F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant
Supplementary Table S2 from [<sup>18</sup>F]FDG and [<sup>18</sup>F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant Open
Suppl. Table 2. Various clinicopathological features of the 16 patients.
View article: Supplementary Methods S1 from [<sup>18</sup>F]FDG and [<sup>18</sup>F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant
Supplementary Methods S1 from [<sup>18</sup>F]FDG and [<sup>18</sup>F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant Open
Supplementary Methods
View article: Supplementary Figure S2 from [<sup>18</sup>F]FDG and [<sup>18</sup>F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant
Supplementary Figure S2 from [<sup>18</sup>F]FDG and [<sup>18</sup>F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant Open
Suppl. Fig. 2. The correspondence between the SUVmax values and the SUVpeak values of [18F]FDG and [18F]FES for the lesions with the highest uptake. Lesions have been indicated per patient.
View article: Supplementary Table S4 from [<sup>18</sup>F]FDG and [<sup>18</sup>F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant
Supplementary Table S4 from [<sup>18</sup>F]FDG and [<sup>18</sup>F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant Open
Suppl. Table 4. Mutation profile of each patient with their corresponding PFS. Data shows that almost all patients with a prolonged PFS (>5 months) harbor an ESR1 mutation
View article: Supplementary Figure S4 from [<sup>18</sup>F]FDG and [<sup>18</sup>F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant
Supplementary Figure S4 from [<sup>18</sup>F]FDG and [<sup>18</sup>F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant Open
Suppl. Fig. 4. Relationship between the various quantitative parameters and ESR1 mutation status. Overall, data shows that quantitative parameters were not affected significantly by ESR1 mutations (Mann-Whitney U test). However, a trend co…
View article: Supplementary Figure S3 from [<sup>18</sup>F]FDG and [<sup>18</sup>F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant
Supplementary Figure S3 from [<sup>18</sup>F]FDG and [<sup>18</sup>F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant Open
Suppl. Fig. 3. Relationship between the various quantitative parameters and PFS. Data shows that patients with a PFS ≥2.0 months have lesions that are metabolically more active and have higher ER expression than patients with a PFS of <2.0…
View article: Supplementary Table S5 from [<sup>18</sup>F]FDG and [<sup>18</sup>F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant
Supplementary Table S5 from [<sup>18</sup>F]FDG and [<sup>18</sup>F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant Open
Suppl. Table 5. Median change in [18F]FES uptake (%) between the baseline vs on-treatment [18F]FES scan for each patient and the received doses of rintodestrant. Change in uptake was unrelated to the dose (Spearman's rho, p = 0.65) and PFS…
View article: Supplementary Figure S1 from [<sup>18</sup>F]FDG and [<sup>18</sup>F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant
Supplementary Figure S1 from [<sup>18</sup>F]FDG and [<sup>18</sup>F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant Open
Suppl. Fig. 1. The number of lesions included in the quantitative lesion-based analysis using the [18F]FDG and [18F]FES PET/CT scans. Lesions have been classified per organ type for each patient.
View article: Quantification of neuroinflammation in spinal cord and neuroforamina of patients with painful cervical radiculopathy using [11C]DPA713 PET/CT
Quantification of neuroinflammation in spinal cord and neuroforamina of patients with painful cervical radiculopathy using [11C]DPA713 PET/CT Open
Background Animal models of nerve compression have revealed neuroinflammation not only at the entrapment site, but also remotely at the spinal cord. However, there is limited information on the presence of neuroinflammation in human compre…
View article: Neuroinflammation at the Neuroforamina and Spinal Cord in Patients with Painful Cervical Radiculopathy and Pain-Free Participants: An [11C]DPA713 PET/CT Proof-of-Concept Study
Neuroinflammation at the Neuroforamina and Spinal Cord in Patients with Painful Cervical Radiculopathy and Pain-Free Participants: An [11C]DPA713 PET/CT Proof-of-Concept Study Open
Background/Objectives: The complex pathophysiology of painful cervical radiculopathy is only partially understood. Neuroimmune activation in the dorsal root ganglion and spinal cord is assumed to underlie the genesis of radicular pain. Mol…
View article: Validating image-derived input functions of dynamic 18F-FDG long axial field-of-view PET/CT studies
Validating image-derived input functions of dynamic 18F-FDG long axial field-of-view PET/CT studies Open
Aim/background Dynamic PET imaging requires an input function typically obtained through blood sampling. Image-derived input functions (IDIFs) of the ascending aorta (AA), aortic arch, descending aorta (DA), or left ventricle (LV) offer no…
View article: Physiologically Based Pharmacokinetic Model of Tyrosine Kinase Inhibitors to Predict Target Site Penetration, with <scp>PET</scp>‐Guided Verification
Physiologically Based Pharmacokinetic Model of Tyrosine Kinase Inhibitors to Predict Target Site Penetration, with <span>PET</span>‐Guided Verification Open
Osimertinib, a tyrosine kinase inhibitor (TKI), treats non‐small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. However, its efficacy may vary due to heterogeneous drug distribution, assessable through mic…
View article: Validation of quantitative [18F]NaF PET uptake parameters in bone diseases: a systematic review
Validation of quantitative [18F]NaF PET uptake parameters in bone diseases: a systematic review Open
View article: Feasibility of Using 18F-FDG PET/CT Radiomics and Machine Learning to Detect Drug-Induced Interstitial Lung Disease
Feasibility of Using 18F-FDG PET/CT Radiomics and Machine Learning to Detect Drug-Induced Interstitial Lung Disease Open
Background: Bleomycin is an oncolytic and antibiotic agent used to treat various human cancers because of its antitumor activity. Unfortunately, up to 46% of the patients treated with bleomycin develop drug-induced interstitial lung diseas…
View article: [18F]NaF PET/CT as a Marker for Fibrodysplasia Ossificans Progressiva: From Molecular Mechanisms to Clinical Applications in Bone Disorders
[18F]NaF PET/CT as a Marker for Fibrodysplasia Ossificans Progressiva: From Molecular Mechanisms to Clinical Applications in Bone Disorders Open
Fibrodysplasia ossificans progressiva (FOP) is a rare genetic bone disorder characterized by episodic flare-ups in connective tissue, which are frequently followed by the formation of heterotopic ossification. The absence of available plas…
View article: Pharmacokinetic analysis and simplified uptake measures for tumour lesion [18F]F-AraG PET imaging in patients with non-small cell lung cancer
Pharmacokinetic analysis and simplified uptake measures for tumour lesion [18F]F-AraG PET imaging in patients with non-small cell lung cancer Open
View article: Performance of simplified methods for quantification of [18F]NaF uptake in fibrodysplasia ossificans progressiva
Performance of simplified methods for quantification of [18F]NaF uptake in fibrodysplasia ossificans progressiva Open
Background Fibrodysplasia Ossificans Progressiva (FOP) is a rare, genetic disease in which heterotopic bone is formed in muscles, tendons and ligaments throughout the body. Disease progression is variable over time and between individuals.…
View article: Ultra-low foetal radiation exposure in 18F-FDG PET/CT imaging with a long axial field-of-view PET/CT system
Ultra-low foetal radiation exposure in 18F-FDG PET/CT imaging with a long axial field-of-view PET/CT system Open
View article: Pharmacokinetic analysis and simplified uptake measures for tumour lesion [18F]F-AraG PET imaging in patients with non-small cell lung cancer
Pharmacokinetic analysis and simplified uptake measures for tumour lesion [18F]F-AraG PET imaging in patients with non-small cell lung cancer Open
Introduction The novel positron emission tomography (PET) imaging tracer, [ 18 F]F-AraG, targets activated T-cells, offering a potential means to improve our understanding of immune-oncological processes. The aim of this study was to deter…
View article: Investigating reliable amyloid accumulation in Centiloids: Results from the AMYPAD Prognostic and Natural History Study
Investigating reliable amyloid accumulation in Centiloids: Results from the AMYPAD Prognostic and Natural History Study Open
INTRODUCTION To support clinical trial designs focused on early interventions, our study determined reliable early amyloid‐β (Aβ) accumulation based on Centiloids (CL) in pre‐dementia populations. METHODS A total of 1032 participants from …
View article: Validation of image-derived input function using a long axial field of view PET/CT scanner for two different tracers
Validation of image-derived input function using a long axial field of view PET/CT scanner for two different tracers Open
View article: Endocannabinoid levels in plasma and neurotransmitters in the brain: a preliminary report on patients with a psychotic disorder and healthy individuals
Endocannabinoid levels in plasma and neurotransmitters in the brain: a preliminary report on patients with a psychotic disorder and healthy individuals Open
Background Interactions between the endocannabinoid system (ECS) and neurotransmitter systems might mediate the risk of developing a schizophrenia spectrum disorder (SSD). Consequently, we investigated in patients with SSD and healthy cont…
View article: Comparing parametric methods for longitudinal measurement of β‐amyloid pathology with PET in elderly individuals
Comparing parametric methods for longitudinal measurement of β‐amyloid pathology with PET in elderly individuals Open
Background Amyloid‐β (Aβ) PET is commonly used for studying the earliest phases of Alzheimer’s disease (AD) in cognitively unimpaired (CU) individuals. In this group, the expected changes in Aβ pathology are small, which emphasizes the imp…
View article: Comparing parametric methods for longitudinal measurement of β‐amyloid pathology with PET in elderly individuals
Comparing parametric methods for longitudinal measurement of β‐amyloid pathology with PET in elderly individuals Open
Background Amyloid‐ß (Aß) PET is commonly used for studying the earliest phases of Alzheimer’s disease (AD) in cognitively unimpaired (CU) individuals. In this group, the expected changes in Aß pathology are small, which emphasizes the imp…
View article: A Centiloid cut‐off to help predict true amyloid accumulation
A Centiloid cut‐off to help predict true amyloid accumulation Open
Background Longitudinal amyloid‐PET‐based imaging endpoints are often included in clinical trials, where they provide critical evidence of treatment efficacy. We assessed the longitudinal variability of the Centiloid (CL) scale and its abi…
View article: Hub vulnerability and short path length to entorhinal cortex are associated with tau binding in Alzheimer’s disease: a combined MEG/PET study
Hub vulnerability and short path length to entorhinal cortex are associated with tau binding in Alzheimer’s disease: a combined MEG/PET study Open
Background Brain network studies have revealed that highly connected ‘hub’ regions are particularly vulnerable to Alzheimer’s disease (AD) pathology. Additionally, the ‘‘transneuronal spread” hypothesis proposes that a toxic agent (tau) pr…
View article: A Centiloid cut‐off to help predict true amyloid accumulation
A Centiloid cut‐off to help predict true amyloid accumulation Open
Background Longitudinal amyloid‐PET‐based imaging endpoints are often included in clinical trials, where they provide critical evidence of treatment efficacy. We assessed the longitudinal variability of the Centiloid (CL) scale and its abi…
View article: Mitigating SUV uncertainties using total body PET imaging
Mitigating SUV uncertainties using total body PET imaging Open
Purpose Standardised uptake values (SUV) are commonly used to quantify 18 F-FDG lesion uptake. However, SUVs may suffer from several uncertainties and errors. Long-axial field-of-view (LAFOV) PET/CT systems might enable image-based quality…
View article: NIMG-23. COMBINATION OF ADC MRI AND FET PET FOR THE ASSESSMENT OF QUANTITATIVE TUMOR PRESENCE IN DIFFUSE GLIOMA
NIMG-23. COMBINATION OF ADC MRI AND FET PET FOR THE ASSESSMENT OF QUANTITATIVE TUMOR PRESENCE IN DIFFUSE GLIOMA Open
BACKGROUND Local treatment of diffuse glioma is currently guided by standard MRI sequences. Yet, the combination of apparent diffusion coefficient (ADC) and O-(2-[18F]-fluoroethyl)-L-tyrosine positron emission tomography (FET PET) (ADC/FET…
View article: Harmonization of brain PET images in multi-center PET studies using Hoffman phantom scan
Harmonization of brain PET images in multi-center PET studies using Hoffman phantom scan Open